Type 1 diabetes vaccine development: Animal models vs. humans

Human Vaccines

Volumn 7, Issue 1, 2011, Pages 19-26

  Boettler, Tobias ^a   Von Herrath, Matthias ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Immune homeostasis; Tolerance; Translation; Type 1 diabetes; Vaccination

Indexed keywords

ALUMINUM POTASSIUM SULFATE; AUTOANTIBODY; AUTOANTIGEN; C PEPTIDE; CHROMOGRANIN A; CYTOKINE; DIABETES MELLITUS VACCINE; DNA VACCINE; GLUTAMATE DECARBOXYLASE 65; HEAT SHOCK PROTEIN 60; HLA ANTIGEN; INSULIN; INTERFERON; INTERLEUKIN 10; ISLET SPECIFIC GLUCOSE 6 PHOSPHATASE CATALYTIC SUBUNIT RELATED PROTEIN; ISLET ZINC TRANSPORTER; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PLACEBO; PLASMID DNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VACCINE; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COXSACKIE VIRUS B; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; DIABETES MELLITUS; DIABETOGENESIS; DRUG EFFICACY; HUMAN; HYPERGLYCEMIA; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; MUMPS VIRUS; NONHUMAN; NONOBESE DIABETIC MOUSE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PATHOGENESIS; REVIEW; ROTAVIRUS; RUBELLA VIRUS; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; VACCINATION; VIRUS INFECTION;

EID: 79551693086     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.1.12641     Document Type: Review

References (114)

1. Aly TA, Ide A, Jahromi MM, Barker JM, Fernando MS, Babu SR, et al. Extreme genetic risk for type 1A diabetes. Proc Natl Acad Sci USA 2006; 103:14074-9. (Pubitemid 44452982)
2. Hyttinen V, Kaprio J, Kinnunen L, Koskenvuo M, Tuomilehto J. Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs: a nationwide follow-up study. Diabetes 2003; 52:1052-5. (Pubitemid 36384278)
3. Redondo MJ, Rewers M, Yu L, Garg S, Pilcher CC, Elliott RB, et al. Genetic determination of islet cell autoimmunity in monozygotic twin, dizygotic twin and non-twin siblings of patients with type 1 diabetes: prospective twin study. BMJ 1999; 318:698-702. (Pubitemid 29191993)
4. Ziegler AG, Nepom GT. Prediction and pathogenesis in type 1 diabetes. Immunity 2010; 32:468-78.
5. Haller MJ, Atkinson MA, Schatz D. Type 1 diabetes mellitus: etiology, presentation and management. Pediatr Clin North Am 2005; 52:1553-78. (Pubitemid 41654729)
6. Jahromi MM, Eisenbarth GS. Genetic determinants of type 1 diabetes across populations. Ann N Y Acad Sci 2006; 1079:289-99. (Pubitemid 46001348)
7. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 2005; 48:2221-8.
8. von Herrath M, Nepom GT. Animal models of human type 1 diabetes. Nat Immunol 2009; 10:129-32.
9. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 1999; 5:601-4.
10. Pipeleers D, In't Veld P, Pipeleers-Marichal M, Gorus F. The beta cell population in type 1 diabetes. Novartis Found Symp 2008; 292:19-24.
11. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 2009; 155:173-81.
12. Wu Q, Salomon B, Chen M, Wang Y, Hoffman LM, Bluestone JA, et al. Reversal of spontaneous autoimmune insulitis in nonobese diabetic mice by soluble lymphotoxin receptor. J Exp Med 2001; 193:1327-32. (Pubitemid 32524783)
13. Pinkse GG, Tysma OH, Bergen CA, Kester MG, Ossendorp F, van Veelen PA, et al. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci USA 2005; 102:18425-30. (Pubitemid 43011242)
14. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005; 23:447-85. (Pubitemid 40563177)
15. Shizuru JA, Taylor-Edwards C, Banks BA, Gregory AK, Fathman CG. Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science 1988; 240:659-62.
16. Roep BO, Atkinson M, von Herrath M. Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol 2004; 4:989-97. (Pubitemid 39620073)
17. Van Belle TL, Taylor P, von Herrath MG. Mouse Models for Type 1 Diabetes. Drug Discov Today Dis Models 2009; 6:41-5.
18. Forrest JM, Menser MA, Burgess JA. High frequency of diabetes mellitus in young adults with congenital rubella. Lancet 1971; 2:332-4.
19. Honeyman MC, Coulson BS, Stone NL, Gellert SA, Goldwater PN, Steele CE, et al. Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes. Diabetes 2000; 49:1319-24. (Pubitemid 30624232)
20. Pak CY, Eun HM, McArthur RG, Yoon JW. Association of cytomegalovirus infection with autoimmune type 1 diabetes. Lancet 1988; 2:1-4.
21. Hyoty H, Leinikki P, Reunanen A, Ilonen J, Surcel HM, Rilva A, et al. Mumps infections in the etiology of type 1 (insulin-dependent) diabetes. Diabetes Res 1988; 9:111-6. (Pubitemid 19089947)
22. Clements GB, Galbraith DN, Taylor KW. Coxsackie B virus infection and onset of childhood diabetes. Lancet 1995; 346:221-3.
23. Lonnrot M, Korpela K, Knip M, Ilonen J, Simell O, Korhonen S, et al. Enterovirus infection as a risk factor for beta-cell autoimmunity in a prospectively observed birth cohort: the Finnish Diabetes Prediction and Prevention Study. Diabetes 2000; 49:1314-8. (Pubitemid 30624231)
24. Lonnrot M, Salminen K, Knip M, Savola K, Kulmala P, Leinikki P, et al. Enterovirus RNA in serum is a risk factor for beta-cell autoimmunity and clinical type 1 diabetes: a prospective study. Childhood Diabetes in Finland (DiMe) Study Group. J Med Virol 2000; 61:214-20. (Pubitemid 30257246)
25. Yoon JW, Austin M, Onodera T, Notkins AL. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 1979; 300:1173-9. (Pubitemid 9191515)
26. Green J, Casabonne D, Newton R. Coxsackie B virus serology and Type 1 diabetes mellitus: a systematic review of published case-control studies. Diabet Med 2004; 21:507-14. (Pubitemid 38746267)
27. Seewaldt S, Thomas HE, Ejrnaes M, Christen U, Wolfe T, Rodrigo E, et al. Virus-induced autoimmune diabetes: most beta-cells die through inflammatory cytokines and not perforin from autoreactive (anti-viral) cytotoxic T-lymphocytes. Diabetes 2000; 49:1801-9.
28. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 2009; 5:219-26.
29. von Herrath M. Diabetes: A virus-gene collaboration. Nature 2009; 459:518-9.
30. Foulis AK, Farquharson MA, Meager A. Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 1987; 2:1423-7. (Pubitemid 18010318)
31. Dotta F, Censini S, van Halteren AG, Marselli L, Masini M, Dionisi S, et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recentonset type 1 diabetic patients. Proc Natl Acad Sci USA 2007; 104:5115-20. (Pubitemid 47186185)
32. Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 2009; 324:387-9.
33. Guilherme L, Cunha-Neto E, Coelho V, Snitcowsky R, Pomerantzeff PM, Assis RV, et al. Human heart-infiltrating T-cell clones from rheumatic heart disease patients recognize both streptococcal and cardiac proteins. Circulation 1995; 92:415-20.
34. Horwitz MS, Bradley LM, Harbertson J, Krahl T, Lee J, Sarvetnick N. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med 1998; 4:781-5. (Pubitemid 28331018)
35. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347:911-20.
36. Oldstone MB. Prevention of type I diabetes in nonobese diabetic mice by virus infection. Science 1988; 239:500-2. (Pubitemid 18084314)
37. Filippi CM, Estes EA, Oldham JE, von Herrath MG. Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in mice. J Clin Invest 2009; 119:1515-23.
38. Filippi CM, von Herrath MG. Viral trigger for type 1 diabetes: pros and cons. Diabetes 2008; 57:2863-71.
39. Cooke A, Tonks P, Jones FM, O'Shea H, Hutchings P, Fulford AJ, et al. Infection with Schistosoma mansoni prevents insulin dependent diabetes mellitus in nonobese diabetic mice. Parasite Immunol 1999; 21:169-76. (Pubitemid 29158763)
40. Saunders KA, Raine T, Cooke A, Lawrence CE. Inhibition of autoimmune type 1 diabetes by gastrointestinal helminth infection. Infect Immun 2007; 75:397-407.
41. Raine T, Zaccone P, Mastroeni P, Cooke A. Salmonella typhimurium infection in nonobese diabetic mice generates immunomodulatory dendritic cells able to prevent type 1 diabetes. J Immunol 2006; 177:2224-33. (Pubitemid 44200981)
42. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008; 455:1109-13.
43. Ohsugi T, Kurosawa T. Increased incidence of diabetes mellitus in specific pathogen-eliminated offspring produced by embryo transfer in NOD mice with low incidence of the disease. Lab Anim Sci 1994; 44:386-8.
44. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998; 188:2205-13. (Pubitemid 29028493)
45. Oldstone MB. Viral persistence: mechanisms and consequences. Curr Opin Microbiol 1998; 1:436-41. (Pubitemid 128423259)
46. Cooke A. Review series on helminths, immune modulation and the hygiene hypothesis: how might infection modulate the onset of type 1 diabetes? Immunology 2009; 126:12-7.
47. Zaccone P, Fehervari Z, Jones FM, Sidobre S, Kronenberg M, Dunne DW, et al. Schistosoma mansoni antigens modulate the activity of the innate immune response and prevent onset of type 1 diabetes. Eur J Immunol 2003; 33:1439-49. (Pubitemid 36609163)
48. Faveeuw C, Angeli V, Fontaine J, Maliszewski C, Capron A, Van Kaer L, et al. Antigen presentation by CD1d contributes to the amplification of Th2 responses to Schistosoma mansoni glycoconjugates in mice. J Immunol 2002; 169:906-12. (Pubitemid 34753447)
49. Kanno T, Kim K, Kono K, Drescher KM, Chapman NM, Tracy S. Group B coxsackievirus diabetogenic phenotype correlates with replication efficiency. J Virol 2006; 80:5637-43.
50. Tracy S, Drescher KM, Chapman NM, Kim KS, Carson SD, Pirruccello S, et al. Toward testing the hypothesis that group B coxsackieviruses (CVB) trigger insulin-dependent diabetes: inoculating nonobese diabetic mice with CVB markedly lowers diabetes incidence. J Virol 2002; 76:12097-111. (Pubitemid 35304309)
51. Drescher KM, Kono K, Bopegamage S, Carson SD, Tracy S. Coxsackievirus B3 infection and type 1 diabetes development in NOD mice: insulitis determines susceptibility of pancreatic islets to virus infection. Virology 2004; 329:381-94. (Pubitemid 39423987)
52. Tracy S, Drescher KM, Jackson JD, Kim K, Kono K. Enteroviruses, type 1 diabetes and hygiene: a complex relationship. Rev Med Virol 2010; 20:106-16.
53. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science 2001; 292:1115-8. (Pubitemid 32440925)
54. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005; 122:107-18. (Pubitemid 40977944)
55. Vaarala O, Atkinson MA, Neu J. The "perfect storm" for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability and mucosal immunity. Diabetes 2008; 57:2555-62.
56. Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, Marzotti S, et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 2005; 48:1565-75. (Pubitemid 41175510)
57. Pohjavuori E, Viljanen M, Korpela R, Kuitunen M, Tiittanen M, Vaarala O, et al. Lactobacillus GG effect in increasing IFN-gamma production in infants with cow's milk allergy. J Allergy Clin Immunol 2004; 114:131-6. (Pubitemid 39005129)
58. Marschan E, Kuitunen M, Kukkonen K, Poussa T, Sarnesto A, Haahtela T, et al. Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation. Clin Exp Allergy 2008; 38:611-8. (Pubitemid 351406072)
59. Ljungberg M, Korpela R, Ilonen J, Ludvigsson J, Vaarala O. Probiotics for the prevention of beta cell autoimmunity in children at genetic risk of type 1 diabetes - the PRODIA study. Ann N Y Acad Sci 2006; 1079:360-4. (Pubitemid 44968747)
60. Alyanakian MA, Grela F, Aumeunier A, Chiavaroli C, Gouarin C, Bardel E, et al. Transforming growth factor-beta and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes. Diabetes 2006; 55:179-85. (Pubitemid 43343313)
61. von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, Ku CL, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008; 321:691-6.
62. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 1994; 15:516-42.
63. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996; 85:291-7. (Pubitemid 26160699)
64. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7:622-32. (Pubitemid 47123550)
65. Serreze DV, Chapman HD, Varnum DS, Hanson MS, Reifsnyder PC, Richard SD, et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice. J Exp Med 1996; 184:2049-53.
66. Serreze DV, Fleming SA, Chapman HD, Richard SD, Leiter EH, Tisch RM. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol 1998; 161:3912-8. (Pubitemid 28468965)
67. Bendelac A, Boitard C, Bedossa P, Bazin H, Bach JF, Carnaud C. Adoptive T cell transfer of autoimmune nonobese diabetic mouse diabetes does not require recruitment of host B lymphocytes. J Immunol 1988; 141:2625-8. (Pubitemid 18263044)
68. Ludvigsson J, Heding L, Lieden G, Marner B, Lernmark A. Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. Br Med J (Clin Res Ed) 1983; 286:176-8. (Pubitemid 13147594)
69. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, et al. Rituximab, B-lymphocyte depletion and preservation of beta-cell function. N Engl J Med 2009; 361:2143-52.
70. Martin S, Wolf-Eichbaum D, Duinkerken G, Scherbaum WA, Kolb H, Noordzij JG, et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001; 345:1036-40.
71. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010; 464:1293-300.
72. Lennon GP, Bettini M, Burton AR, Vincent E, Arnold PY, Santamaria P, et al. T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. Immunity 2009; 31:643-53.
73. Zehn D, Bevan MJ. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 2006; 25:261-70. (Pubitemid 44224142)
74. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4(+) CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005; 54:92-9. (Pubitemid 40105099)
75. von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol 2007; 7:988-94.
76. Stadinski B, Kappler J, Eisenbarth GS. Molecular targeting of islet autoantigens. Immunity 2010; 32:446-56.
77. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005; 435:220-3. (Pubitemid 40685949)
78. Kent SC, Chen Y, Bregoli L, Clemmings SM, Kenyon NS, Ricordi C, et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 2005; 435:224-8. (Pubitemid 40685950)
79. Blanas E, Carbone FR, Allison J, Miller JF, Heath WR. Induction of autoimmune diabetes by oral administration of autoantigen. Science 1996; 274:1707-9. (Pubitemid 26414901)
80. Lang KS, Recher M, Junt T, Navarini AA, Harris NL, Freigang S, et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 2005; 11:138-45. (Pubitemid 40321348)
81. Martinic MM, von Herrath MG. Real-time imaging of the pancreas during development of diabetes. Immunol Rev 2008; 221:200-13. (Pubitemid 351230108)
82. Eriksson U, Ricci R, Hunziker L, Kurrer MO, Oudit GY, Watts TH, et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 2003; 9:1484-90. (Pubitemid 38004775)
83. Muir A, Peck A, Clare-Salzler M, Song YH, Cornelius J, Luchetta R, et al. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription. J Clin Invest 1995; 95:628-34.
84. Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 2010; 34:408-15.
85. Ludvigsson J, Faresjo M, Hjorth M, Axelsson S, Cheramy M, Pihl M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359:1909-20.
86. Fousteri G, Dave A, Bot A, Juntti T, Omid S, von Herrath M. Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma. Diabetologia 2010.
87. + regulatory T-cells. Diabetes 1999; 48:2150-6.
88. Aspord C, Thivolet C. Nasal administration of CTBinsulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice. Clin Exp Immunol 2002; 130:204-11. (Pubitemid 35286206)
89. + regulatory T cell function via innate TLR2 signaling. J Clin Invest 2006; 116:2022-32.
90. Martinez NR, Augstein P, Moustakas AK, Papadopoulos GK, Gregori S, Adorini L, et al. Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J Clin Invest 2003; 111:1365-71. (Pubitemid 36554707)
91. Kobayashi M, Abiru N, Arakawa T, Fukushima K, Zhou H, Kawasaki E, et al. Altered B:9-23 insulin, when administered intranasally with cholera toxin adjuvant, suppresses the expression of insulin autoantibodies and prevents diabetes. J Immunol 2007; 179:2082-8.
92. Hanninen A, Martinez NR, Davey GM, Heath WR, Harrison LC. Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity. J Clin Invest 2002; 109:261-7. (Pubitemid 34083746)
93. Maron R, Palanivel V, Weiner HL, Harn DA. Oral administration of schistosome egg antigens and insulin B-chain generates and enhances Th2-type responses in NOD mice. Clin Immunol Immunopathol 1998; 87:85-92. (Pubitemid 28194166)
94. Slavin AJ, Maron R, Weiner HL. Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes. Int Immunol 2001; 13:825-33. (Pubitemid 32514708)
95. Ploix C, Bergerot I, Fabien N, Perche S, Moulin V, Thivolet C. Protection against autoimmune diabetes with oral insulin is associated with the presence of IL-4 type 2 T-cells in the pancreas and pancreatic lymph nodes. Diabetes 1998; 47:39-44. (Pubitemid 28030805)
96. Hancock WW, Polanski M, Zhang J, Blogg N, Weiner HL. Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta and prostaglandin-E. Am J Pathol 1995; 147:1193-9.
97. Homann D, Dyrberg T, Petersen J, Oldstone MB, von Herrath MG. Insulin in oral immune "tolerance": a one-amino acid change in the B chain makes the difference. J Immunol 1999; 163:1833-8.
98. Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. J Exp Med 1996; 184:2167-74.
99. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002; 346:1685-91.
100. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial - Type 1. Diabetes Care 2005; 28:1068-76. (Pubitemid 40616615)
101. Nanto-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008; 372:1746-55.
102. Skyler JS. Update on worldwide efforts to prevent type 1 diabetes. Ann N Y Acad Sci 2008; 1150:190-6.
103. Harrison LC. Vaccination against self to prevent autoimmune disease: the type 1 diabetes model. Immunol Cell Biol 2008; 86:139-45. (Pubitemid 351301764)
104. Bergerot I, Fabien N, Mayer A, Thivolet C. Active suppression of diabetes after oral administration of insulin is determined by antigen dosage. Ann N Y Acad Sci 1996; 778:362-7. (Pubitemid 26145562)
105. Achenbach P, Barker J, Bonifacio E. Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr Diab Rep 2008; 8:87-93.
106. Chaillous L, Lefevre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet 2000; 356:545-9. (Pubitemid 30611859)
107. Pozzilli P, Pitocco D, Visalli N, Cavallo MG, Buzzetti R, Crino A, et al. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 2000; 43:1000-4. (Pubitemid 30655719)
108. Eldor R, Kassem S, Raz I. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results. Diabetes Metab Res Rev 2009; 25:316-20.
109. Solvason N, Lou YP, Peters W, Evans E, Martinez J, Ramirez U, et al. Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites. J Immunol 2008; 181:8298-307.
110. Tsai S, Shameli A, Yamanouchi J, Clemente-Casares X, Wang J, Serra P, et al. Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 2010; 32:568-80.
111. Bresson D, Fradkin M, Manenkova Y, Rottembourg D, von Herrath M. Genetic-induced Variations in the GAD65 T-cell Repertoire Governs Efficacy of Anti-CD3/GAD65 Combination Therapy in New-onset Type 1 Diabetes. Mol Ther 2010; 18:307-16.
112. Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006; 116:1371-81.
113. Mastrandrea L, Yu J, Behrens T, Buchlis J, Albini C, Fourtner S, et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009; 32:1244-9.
114. Bresson D, von Herrath M. Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside. Diabetes Care 2009; 32:1753-68.